Drugs / Risankizumab-800CW
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06606808 | Nov 2024 → Aug 2025 overdue | Crohn disease, ulcerative colitis | University Medical Center Groningen | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Risankizumab-800CW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06606808 ↗ |
| Known as | Risankizumab | “Risankizumab is a human monoclonal antibody against IL23 p19, part of a pro-inflammatory cytokine that mediates the inflammatory response in IBD upon binding to its receptor.” NCT06606808 ↗ |
| Modality | Monoclonal antibody | “Risankizumab is a human monoclonal antibody against IL23 p19” NCT06606808 ↗ |
| Route | Intravenous | “Risankizumab-800CW will be administered intravenously.” NCT06606808 ↗ |